Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-Year follow up

AIDS

Volumn 18, Issue 9, 2004, Pages 1321-1325

  Vincent, Emmanuelle ^a   Bouhnik, Anne Déborah ^a   Carrieri, Maria Patrizia ^a   Rey, Dominique ^a   Dujardin, Pierre ^b   Granier, Françoise ^c   Fuzibet, Jean Gabriel ^d   Obadia, Yolande ^a   Moatti, Jean Paul ^a   Spire, Bruno ^a  

^a OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^b Monaco Hospital   (Monaco)

^c Mantes Hospital   (France)

^d Ophthalmology Department   (France)

Author keywords

HAART; HIV; Injecting drug users; Self perceived side effects; Sexual behaviours

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; FEMALE; FOLLOW UP; HEALTH VISITOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SAFE SEX; SEXUAL BEHAVIOR; SEXUALITY; SIDE EFFECT; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; RISK-TAKING; SAFE SEX; SEXUAL PARTNERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 3042541842     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200406180-00011     Document Type: Article

References (30)

1. Aalen OO, Farewell VT, De Angelis D, Day NE, Gill ON. New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected. AIDS 1999, 13:103-108.
2. Scheer S, Chu PL, Klausner JD, Katz MH, Schwarcz SK. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001, 357:432-435.
3. Elford J, Bolding C, Sherr L. High-risk sexual behaviour increases among London gay men between 1998 and 2001: what is the role of HIV optimism? AIDS 2002, 16:1537-1544.
4. Rietmeijer CA, Patnaik JL, Judson FN, Douglas JMJ. Increases in gonorrhea and sexual risk behaviors among men who have sex with men: a 12-year trend analysis at the Denver Metro Health Clinic. Sex Transm Dis 2003, 30:562-567.
5. Vlahov D, Safaien M, Lai S, Strathdee SA, Johnson L, Sterling T, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001, 15:2311-2316.
6. Bouhnik AD, Moatti JP, Vlahov D, Gallais H, Dellamonica P, Obadia Y. Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Community Health 2002, 56:349-353.
7. Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 2002, 16:775-780.
8. DiClemente RJ, Funkhouser E, Wingood C, Fawal H, Holmberg SD, Vermund SH. Protease inhibitor combination therapy and decreased condom use among gay men. South Med J 2002, 95:421-425.
9. Tun W, Celentano DD, Vlahov D, Strathdee SA. Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug users. AIDS 2003, 17:1953-1962.
10. Blanch J, Rousaud A, Martinez E, De Lazzari E, Peri JM, Milinkovic A, et al. Impact of lipodystrophy on the quality of life of HIV-1-infected patients, J Acquir Immune Defic Syndr 2002,31:404-407.
11. Carrieri P, Spire B, Duran S, Katlama C, Peyramond D, François C, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003, 32:38-47.
12. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HCT 2001, 2:38-45.
13. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001, 28:445-449.
14. Desquilbet L, Deveau C, Coujard C, Hubert JB, Derouineau J, Meyer L. Increase in at-risk sexual behaviour among HIV-1-infected patients followed in the French PRIMO cohort. AIDS 2002, 16:2329-2333.
15. Wolf K, Young J, Rickenbach M, Vernazza P, Flepp M, Furrer H, et al. Prevalence of unsafe sexual behavior among HIV-infected individuals: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2003, 33:494-499.
16. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J, et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 2000, 14:151-155.
17. Furher R, Rouillon F. La version française de l'échelle CES-D. Description and translation of the auto-evaluation (in French). Psychiatrie et Psychobiologie 1989, 4:163-166.
18. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986, 73:13-22.
19. Booth RE, Kwiatkowski CF, Chitwood DD. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend 2000, 58:219-226.
20. Miguez-Burbano MJ, Pineda-Medina L, Lecusay R, et al. Continued high risk behaviors in HIV infected drug abusers. J Addict Dis 2002, 21:67-80.
21. Rhodes T, Ball A, Stimson CV, Kobyshcha Y, Fitch C, Pokrovsky V, et al. HIV infection associated with drug injecting in the newly independent states, eastern Europe: the social and economic context of epidemics. Addiction 1999, 94:1323-1336.
22. Kwiatkowshi CF, Stober DR, Booth RE, Zhang Y. Predictors of increased condom use following HIV intervention with heterosexually active drug users. Drug Alcohol Depend 1999, 54:57-62.
23. Robins AC, Dew MA, Kingsley LA, Becker JT. Do homosexual and bisexual men who place others at potential risk for HIV have unique psychological profiles? AIDS Educ Prev 1997, 9:239-251.
24. Strathdee SA, Hogg RS, Martindale SL, Cornelisse PC, Craib KJ, Montaner JS, et al. Determinants of sexual risk-taking among young HIV-negative gay and bisexual. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:61-66.
25. Myers HF, Javanbakht M, Martinez M, Obediah S. Psychosocial predictors of risky sexual behaviors in African American men: implications for prevention. AIDS Educ Prev 2003, 15:66-79.
26. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 2002, 54:1481-1496.
27. Watkins KE, Metzger D, Woody C, McLellan AT. Determinants of condom use among intravenous drug users. AIDS 1993, 7:719-723.
28. Booth RE, Crowley TJ, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend 1996, 42:11-20.
29. Duran S, Solas C, Spire B, Carrieri MP, Fuzibet JC Costagliola D, et al. Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy? A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. AIDS 2001, 15:1075-1077.
30. Andrews C, Slade T. Interpreting scores on the Kessler Psychological Distress Scale (K10). Aust N Z J Public Health 2001, 25:494-497.